Therapy for Treatment-experienced Patients

Ritonavir-boosted Darunavir (Prezista) Is Well Tolerated by Treatment-experienced Patients in POWER 1, 2 and 3 Trials - 8/29/06

Four Drugs No Better than Three for First-line Efavirenz-Based Therapy  - 8/22/06

Reasons for Adverse SMART Outcomes Remain Poorly Understood  - 8/18/06

48-Week Analysis of Lopinavir/Ritonavir Monotherapy Compared to LPV/r + Zidovudine/Lamivudine   - 8/18/06

Safety and Efficacy of Maraviroc, a CCR5 Antagonist, for the Treatment of Treatment-experienced Patients Infected with Dual/Mixed-tropic HIV   - 8/18/06

A Phase II Study of the Safety and Efficacy of the CCR5 Antagonist Vicriviroc   - 8/18/06

48-week Data on TMC 125, a Next Generation Experimental NNRTI from Tibotec Pharmaceuticals   - 8/18/06

Impact of Prior PI Usage on Week 48 Responses to Tipranavir Boosted with Ritonavir   - 8/18/06

Four-year Analysis of Tenofovir/Didanosine Combination Therapy Effects on Lymphocytes, CD4 and Viral Load   - 8/18/06

New Insights on Use by AIDS Patients of Pfizer’s Experimental CCR5 Antagonist Maraviroc   - 8/15/06

Darunavir Provides Durable HIV Suppression in Treatment-experienced Patients: Week 48 analysis of POWER 1 and 2   - 8/15/06